During the past decade, Tokyo Medical University Hospital conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 10 clinical trials were completed, i.e. on average, 58.8% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 9 clinical trials were completed. i.e. 112.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Medical University Hospital" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Tokyo Medical University" with 2 trials sponsored, "Allergan" with 1 trials sponsored and "Amgen" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical University Hospital" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Chiba University" with 1 trials as a collaborator, "China Medical University, Taiwan" with 1 trials as a collaborator, "Japan Lung Cancer Society" with 1 trials as a collaborator and "Japan Society for the Promotion of Science (JSPS)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Medical University Hospital" are "Generalized Pustular Psoriasis" (3 trials), "Psoriasis" (3 trials), "Alopecia Areata" (2 trials), "Atopic Dermatitis" (2 trials) and "Alzheimer Disease" (1 trials). Many other conditions were trialed in "Tokyo Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Medical University Hospital" are "Drug" (18 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Baricitinib" (4 trials), "Spesolimab" (4 trials), "Mirikizumab" (2 trials) and "Abicipar Pegol" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Medical University Hospital" are 19 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Tokyo Medical University Hospital". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Tokyo Medical University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Medical University Hospital, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".